(Q46509828)

English

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

0 references

14

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Martin Bornhäuser

15

object named as

Martin Bornhäuser

1 reference

Europe PubMed Central

22 December 2017

16

object named as

Francis Ayuk

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

author name string

Nicolaus Kröger

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Bronwen Shaw

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Simona Iacobelli

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Tatjana Zabelina

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Karl Peggs

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Avichai Shimoni

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Arnon Nagler

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Thomas Binder

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Thomas Eiermann

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Alejandro Madrigal

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Rainer Schwerdtfeger

11

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Michael Kiehl

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Herbert Gottfried Sayer

13

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Axel Rolf Zander

17

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

David I Marks

18

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group

19

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

British Journal of Haematology

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

129

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

631-643

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Anti-myeloma activity of natural killer lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05513.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05513.X

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15916686

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46509828&oldid=2156805376"